IQVIA Hlds (IQV) Stock Forecast & Price Target

IQVIA Holdings demonstrates a positive outlook driven by strong performance in its Focused Scientific and Patient (FSP), Real World Evidence (RWE), and Clinical and Strategic Management Services (CSMS) segments, all of which experienced year-over-year growth in Q3. The company is also benefiting from improved client decision timelines and a robust pipeline, supported by recent drug launches, which is expected to contribute to a growth rate of over 4% on a constant currency basis in the Research and Development Services (R&DS) segment, excluding COVID-related impacts. Furthermore, the pricing environment has improved, allowing IQVIA to strategically walk away from less favorable deals, showcasing its commitment to maintaining value and quality in its offerings.

IQVIA Holdings has reported a year-over-year constant currency growth of 3.8%, reflecting a decline from 6.8% in the previous quarter, which raises concerns about the company's ability to maintain robust revenue growth. The company anticipates that if reported revenue growth in 2026 falls below 5%, it would indicate a disappointing performance, especially given the challenges posed by tough year-over-year comparisons and margins affected by passthroughs. Additionally, rising interest rates could adversely impact earnings, further complicating the company's financial outlook despite management's reassurances regarding revenue stability.